Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.

doi:10.1158/1078-0432.CCR-25-4001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2026

Munzur Aslı D, Herberts Cameron, Kwan Edmond M, Emmett Louise, Sandhu Shahneen, Buteau James P, Iravani Amir, Joshua Anthony M, Francis Roslyn J, Lee Sze-Ting, Scott Andrew M, Martin Andrew J, Stockler Martin R, Zhang Alison Y, Williams Scott G, Bernales Cecily Q, Donnellan Gráinne, Koudjanian Melissa, Parekh Karan, Bacon Jack V W, Karsan Aly, Azad Arun A, Davis Ian D, Hofman Michael S, Wyatt Alexander W

Abstract excerpt

PURPOSE: Clonal hematopoiesis (CH) is a precursor state linked to risk of hematologic neoplasms and may be exacerbated by radiation exposure. We aimed to compare CH prevalence after the new radioligand therapy 177Lu-PSMA-617 versus the alternative standard-of-care cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). EXPERIMENTAL DESIGN: This post hoc correlative analysis used...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clonal Hematopoiesis

Share to Dipeptides

Share to Mutation

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to Radiopharmaceuticals

Share to Taxoids

Source

Open in PubMed

Identifiers

PMID: 41649873
DOI: 10.1158/1078-0432.CCR-25-4001

Genes

PPM1D

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.PMID 41649873Read ↗

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancerSemantic proximity Read ↗

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).Semantic proximity Read ↗

Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomesSemantic proximity Read ↗

Distinct landscape and clinical implications of therapy-related clonal hematopoiesis.Semantic proximity Read ↗

Analysis of evolutionary dynamics and clonal architecture in prostate cancerSemantic proximity Read ↗

Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancerSemantic proximity Read ↗

Implications of Clonal Hematopoiesis for Precision OncologySemantic proximity Read ↗

A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease.Semantic proximity Read ↗

Risk of Clonal Hematopoiesis of Indeterminate Potential after Cancer Radiation TherapySemantic proximity Read ↗

Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI- Driven BiomarkersSemantic proximity Read ↗

Differential Response to 177Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing InterferenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.